29 Aug, 2026 New Data from ATTR and Hypertension Programs Presented at the European Society of Cardiology (ESC) Congress 2026 Demonstrate Strength of RNAi-Powered Silencing

New analyses presented at ESC reinforced the clinical profile of vutrisiran across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease, and the potential application of RNAi to uncontrolled hypertension.

A late-breaking prespecified subgroup analysis of the HELIOS-B Phase 3 study demonstrated that vutrisiran provides consistent clinical benefit across all-cause mortality and recurrent cardiovascular events in patients, irrespective of baseline tafamidis use. 

Hamatani, et al. "Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy”

Damy, et al. "Amylo'ExTTRa: Exploring Extra-Cardiac Manifestations in Patients with ATTR-CM Using a French National Health Data System"

Lairez, et al. "Vutrisiran is Associated with Preservation of Intrinsic Capacity and Healthy Ageing in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Post Hoc Analysis of HELIOS-B"

Schwarting, et al. "Fewer Adverse Events Reported in ATTR-CM Patients Treated with Vutrisiran Versus Placebo: Post Hoc Safety Analysis from HELIOS-B"